肠道微生物来源的N-乙酰胞壁酸通过AKT1通路缓解结直肠癌
该研究通过宏基因组分析7个独立队列(n=1121)发现结直肠癌患者肽聚糖合成酶基因相对丰度全面降低,靶向质谱鉴定出结直肠癌患者中N-乙酰胞壁酸(NAM)显著耗竭且随肿瘤进展而下降(p<0.001)。多种小鼠模型和患者来源类器官实验显示NAM抑制肠道肿瘤发生,机制上NAM直接结合AKT1并阻断其磷酸化。结论认为NAM靶向AKT1信号通路保护肠道免受肿瘤发生,可能作为结直肠癌的新型潜在预防和治疗生物标志物。
要点
- 结直肠癌患者肽聚糖合成酶基因相对丰度全面降低,NAM显著耗竭且随肿瘤进展下降(p<0.001)。
- NAM在Apc Min/+、AOM/DSS处理及MC38荷瘤小鼠等多种模型中显著抑制肠道肿瘤发生。
- NAM以浓度依赖性方式抑制患者来源结直肠癌类器官生长,机制为直接结合AKT1并阻断其磷酸化。
核心结论
- 肽聚糖片段NAM通过靶向AKT1信号通路保护肠道免受肿瘤发生。
- NAM可能作为结直肠癌的新型潜在预防和治疗生物标志物。
研究设计与样本
- 通过宏基因组分析评估肽聚糖合成酶和水解酶基因的相对丰度。
- 采用靶向质谱定量结直肠癌患者粪便和血清中的特定肽聚糖片段。
- 利用多种结直肠癌小鼠模型和患者来源类器官系统评估肽聚糖片段对肠道肿瘤发生的影响。
- 通过蛋白质组微阵列、转录组测序和拯救实验筛选并评估下游分子靶点。
主要发现
- 7个独立队列(n=1121)宏基因组分析显示结直肠癌患者肽聚糖合成酶基因相对丰度全面降低。
- 靶向质谱鉴定出结直肠癌患者中特定肽聚糖片段NAM显著耗竭,且随肿瘤进展而下降(p<0.001)。
- NAM在Apc Min/+、AOM/DSS处理及MC38荷瘤小鼠等多种模型中显著抑制肠道肿瘤发生。
- NAM以浓度依赖性方式抑制患者来源结直肠癌类器官生长。
- 机制上NAM通过直接结合AKT1并阻断其磷酸化来抑制AKT1激活,这是NAM抗癌作用的部分中介。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Gut microbial metabolites are recognised as critical effector molecules that influence the development of colorectal cancer (CRC). Peptidoglycan fragments (PGFs) produced by microbiota play a crucial role in maintaining intestinal homeostasis, but their role in CRC remains unclear. OBJECTIVE: Here, we aimed to explore the potential contribution of PGFs in intestinal tumourigenesis. DESIGN: The relative abundance of peptidoglycan synthase and hydrolase genes was assessed by metagenomic analysis. Specific PGFs in the faeces and serum of CRC patients were quantified using targeted mass spectrometry. The effects of PGF on intestinal tumourigenesis were systematically evaluated using various murine models of CRC and organoids derived from CRC patients. Downstream molecular targets were screened and evaluated using proteome microarray, transcriptome sequencing and rescue assays. RESULTS: Metagenomic analysis across seven independent cohorts (n=1121) revealed a comprehensive reduction in peptidoglycan synthase gene relative abundance in CRC patients. Targeted mass spectrometry identified significant depletion of a specific PGF, N-acetylmuramic acid (NAM) in CRC patients, which decreased as tumours progressed (p<0.001). NAM significantly inhibits intestinal tumourigenesis in various models, including Apc Min/+, AOM/DSS-treated and MC38 tumour-bearing mice. Additionally, NAM inhibits the growth of patient-derived CRC organoids in a concentration-dependent manner. Mechanistically, NAM inhibits the activation of AKT1 by directly binding to it and blocking its phosphorylation, which is a partial mediator of NAM's anticancer effects. CONCLUSION: The PGF NAM protects against intestinal tumourigenesis by targeting the AKT1 signalling pathway. NAM may serve as a novel potential preventive and therapeutic biomarker against CRC.
引用
- Hu M, Xu Y, Wang Y, et al. Gut microbial-derived N-acetylmuramic acid alleviates colorectal cancer via the AKT1 pathway. Gut. 2025. PMID: 40015949. doi:10.1136/gutjnl-2024-332891
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。